Samsung Bioepis launches Opuviz syringe in Europe

The new presentation expands the European availability of Samsung Bioepis’ aflibercept biosimilar following the launch of its vial format in May 2026.

Samsung Bioepis has launched the pre-filled syringe presentation of Opuviz, its aflibercept biosimilar referencing Eylea, in Europe.

The company said the 40 mg/mL solution in a pre-filled syringe became commercially available from 10 August 2026. The launch follows the introduction of the product’s vial presentation in Europe in May.

The single-dose, ready-to-use presentation is intended to provide ophthalmologists with an additional administration option for intravitreal treatment. Availability and prescribing information may vary between European countries.

Opuviz contains aflibercept, a vascular endothelial growth factor inhibitor used to limit abnormal blood-vessel growth and leakage in the eye. The European Medicines Agency classifies Opuviz as a biosimilar medicine that is highly similar to its reference product, Eylea.

The product is authorised in the European Union for treating adults with neovascular, or wet, age-related macular degeneration; visual impairment caused by macular oedema following retinal vein occlusion; diabetic macular oedema; and myopic choroidal neovascularisation.

Opuviz was initially authorised in the European Union in November 2024. Current European product information covers both vial and pre-filled syringe presentations.

Samsung Bioepis also markets its aflibercept biosimilar in South Korea under the brand name Afilivu.